The first-in-human trial of its Freedom system will evaluate a one-year, under-the-skin sensor that links directly with the user’s smartphone, doing away with the need for additional on-body hardware and making a CGM as discreet as possible.
The early feasibility study will explore the device’s design, safety and Bluetooth communication capabilities, ahead of Senseonics’ plans to launch a pivotal trial in people with diabetes next year. If all goes well, the company said it is eyeing a potential commercial launch in 2028.